SODIUM ZIRCONIUM CYCLOSILICATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for SODIUM ZIRCONIUM CYCLOSILICATE (SODIUM ZIRCONIUM CYCLOSILICATE).
Comprehensive clinical and safety monograph for SODIUM ZIRCONIUM CYCLOSILICATE (SODIUM ZIRCONIUM CYCLOSILICATE).
FDA-approved: Treatment of hyperkalemia in adults.Off-label: Chronic hyperkalemia management in patients on renin-angiotensin-aldosterone system inhibitors; acute hyperkalemia in emergency settings (limited data).
Sodium zirconium cyclosilicate is a non-absorbed, inorganic, potassium-selective cation exchanger that binds potassium ions in the gastrointestinal tract, thereby reducing the absorption of potassium and facilitating its fecal excretion. It exchanges sodium and hydrogen for potassium in the gut lumen.
| Metabolism | Sodium zirconium cyclosilicate is not systemically absorbed and is eliminated unchanged in feces. No hepatic metabolism or cytochrome P450 involvement. |
| Excretion | Primarily eliminated unchanged in feces (>99%); negligible renal excretion (<1%) as the drug is not absorbed systemically. |
| Half-life | Not applicable as the drug acts locally in the GI tract without systemic absorption; clinical effect persists for duration of dosing. |
| Protein binding | Not applicable; <0.1% absorbed systemically, so protein binding is negligible. |
| Volume of Distribution | Not applicable; negligible systemic distribution due to lack of absorption (Vd not measurable). |
| Bioavailability | Oral: <0.1% due to minimal absorption; acts locally in gastrointestinal tract. |
| Onset of Action | Oral: reduction in serum potassium begins within 1 hour; maximal effect may take 24–48 hours. |
| Duration of Action | Duration of action is dependent on dosing interval; sustained effect with repeated administration; potassium lowering persists for at least 24 hours after each dose. |
| Molecular Weight | 1792.05 |
5 g orally three times daily.
| Dosage form | POWDER, FOR SUSPENSION |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for any degree of hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; use with caution due to potential for electrolyte disturbances. |
| 1st trimester | Limited human data; animal studies show no evidence of harm. Use only if clearly needed. |
| 2nd trimester | No known risk; however, consider potential electrolyte disturbances (e.g., hypokalemia) that may affect pregnancy. |
| 3rd trimester | May cause electrolyte imbalances in neonates if used near term. Avoid if possible. |
Clinical note
Comprehensive clinical and safety monograph for SODIUM ZIRCONIUM CYCLOSILICATE (SODIUM ZIRCONIUM CYCLOSILICATE).
| Placental transfer | Not studied in humans. Based on molecular weight (1792.05 Da) and structure, placental transfer is likely minimal; however, definitive data lacking. |
| Breastfeeding | Excretion into breast milk unknown. Due to low oral bioavailability of sodium zirconium cyclosilicate, systemic absorption in infant is unlikely. However, monitor infant for electrolyte disturbances. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Limited human data; animal studies show no teratogenic effects at clinically relevant exposures. Not associated with structural abnormalities in first trimester. Theoretical risk of electrolyte disturbances affecting fetal development if maternal electrolyte imbalance occurs. No known risk in second or third trimester. |
| Fetal Monitoring | Serum potassium levels before and during therapy; monitor for hypokalemia. Serum magnesium, sodium, and bicarbonate periodically. Fetal monitoring only if maternal electrolyte disturbances occur; no specific fetal monitoring required. |
| Fertility Effects | No human data on fertility effects. Animal studies show no impairment of male or female fertility at doses up to 10 times the maximum recommended human dose (based on body surface area). |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to sodium zirconium cyclosilicate or any componentPatients with pre-existing hypokalemia (serum potassium ≤3.5 mEq/L) prior to treatment initiation
| Precautions | Edema: Contains sodium; caution in patients with heart failure or requiring sodium restriction (each 5 g dose provides ~400 mg sodium)., Gastrointestinal effects: Constipation, fecal impaction (especially in elderly or those with decreased GI motility)., Hypokalemia: Monitor serum potassium regularly; may cause hypokalemia if not titrated appropriately., Drug interactions: Separate dosing from oral medications (take at least 2 hours apart) due to potential adsorption., Severe constipation: Discontinue if bowel obstruction suspected. |
| Food/Dietary | No specific food restrictions. However, patients should continue to follow dietary potassium restrictions as advised by their healthcare provider. SZC works in the gastrointestinal tract and does not interfere with food absorption. Avoid taking with high-fat meals as it may delay the onset of action. |
| Clinical Pearls | Sodium zirconium cyclosilicate (SZC) is a non-absorbed potassium binder for chronic hyperkalemia. Onset of action is 1 hour; typically used for maintenance after acute correction. Do not use as emergency treatment for life-threatening hyperkalemia (prefer IV calcium, insulin+glucose). Administer at least 2 hours apart from other oral medications due to potential binding. Monitor serum potassium regularly; adjust dose based on potassium levels. Avoid in patients with severe constipation, bowel obstruction, or impaction. |
| Patient Advice | Take this medication exactly as prescribed, usually three times a day with meals for the first 24-72 hours, then once daily. · Do not crush or chew the powder; mix the packet with about 3 tablespoons (45 mL) of water and drink immediately. · Separate this medication from other oral medicines by at least 2 hours to avoid affecting their absorption. · You may experience constipation or swelling (edema); report severe constipation or swelling to your healthcare provider. · Do not use as a rescue treatment for sudden high potassium; seek emergency care if you have chest pain, irregular heartbeat, or muscle weakness. |
Loading safety data…